drugset
Drugs / IL-2-secreting CD40L-expressing autologous B-CLL cells
last change Mar 2010 re-read 3 minutes ago

IL-2-secreting CD40L-expressing autologous B-CLL cells

Cell therapy

Developed for
B-cell chronic lymphocytic leukemia
Investigated by
Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · The Methodist Hospital Research Institute

Trials 1

today NCT00058786 · Ph 1
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00058786 Dec 2002 → Mar 2010 B-cell chronic lymphocytic leukemia Baylor College of Medicine Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IL-2-secreting CD40L-expressing autologous B-CLL cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT00058786 ↗
Modality Cell therapy “the modified cancer cells will be injected under the skin” NCT00058786 ↗
Route Subcutaneous “the modified cancer cells will be injected under the skin” NCT00058786 ↗